ストックスクリーナーアプリを入手
1.89
2.72%
0.05
アフターアワーズ：
1.80
-0.09
-4.76%
Reviva Pharmaceuticals Holdings Inc (RVPH) 最新ニュース
Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Drops By 35.9% - MarketBeat
Reviva to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Reviva to Participate in the 2025 BIO CEO & Investor Conference -January 30, 2025 at 08:01 am EST - Marketscreener.com
Reviva CEO Reveals Next-Gen Mental Health Drug Strategy at Major Biotech Summit - StockTitan
HC Wainwright Has Positive Outlook for RVPH FY2024 Earnings - Defense World
HC Wainwright Has Bullish Outlook for RVPH FY2024 Earnings - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
HC Wainwright Issues Pessimistic Forecast for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives “Buy” Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Unusual Options Activity - Benzinga
Stock Traders Purchase Large Volume of Reviva Pharmaceuticals Call Options (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Given Buy Rating at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 35.9% in December - MarketBeat
Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.25 - Defense World
Geode Capital Management LLC Buys 42,376 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals stock rated buy by Roth/MKM, backed by Phase 3 results - Investing.com Nigeria
Roth Mkm Begins Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Buy at Maxim Group - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital - Defense World
Maxim Group raises Reviva stock to Buy, sets new target By Investing.com - Investing.com Australia
Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Target Price at $11.25 - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Roth Capital - MarketBeat
Maxim Group Upgrades Reviva Pharmaceuticals (NASDAQ:RVPH) to Buy - MarketBeat
Roth MKM Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy Recommendation - MSN
Maxim Group raises Reviva stock to Buy, sets new target - Investing.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Coverage Initiated at Roth Mkm - MarketBeat
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit -January 07, 2025 at 08:02 am EST - Marketscreener.com
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit - GlobeNewswire
Reviva Pharmaceuticals CEO to Present at Lytham Partners Healthcare Summit 2025 - StockTitan
Reviva Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals to Participate in the UBS Global Healthcare Conference - Marketscreener.com
What is Zacks Small Cap’s Estimate for RVPH FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RVPH Issued By Zacks Small Cap - MarketBeat
RVPH: Preliminary OLE Readout - Yahoo Finance
Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance
Reviva Pharmaceuticals Announces Positive Preliminary Data from RECOVER Trial – - Defense World
Reviva announces pricing of $18M public offering of common stock and warrants - MSN
Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering - MarketWatch
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
Reviva Pharmaceuticals Announces $18M Public Offering with Warrant Package to Fund R&D Pipeline - StockTitan
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - GlobeNewswire
Reviva Announces Proposed Public Offering - The Manila Times
Reviva Pharmaceuticals Launches Public Offering to Fund CNS Drug Development Pipeline - StockTitan
Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results - TipRanks
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia - The Manila Times
3.95%
2.39%
大文字化:
|
ボリューム (24 時間):